Irritable Bowel Syndrome, Diarrhea

Clinical Case Study: Managing Irritable Bowel Syndrome with coMra Therapy

A 71-year-old female patient presented at the center seeking treatment for Irritable Bowel Syndrome (IBS) characterized by a chronic tendency toward diarrhea. At the time of her initial assessment, the patient reported several debilitating symptoms, including periodic bloating, abdominal discomfort, frequent stools, constant moderate pain in the large intestine, and a general sense of weakness and malaise. Notably, the patient had several concomitant health conditions, none of which experienced exacerbation during the course of her coMra therapy.

Initial Treatment and Results

The patient completed two distinct courses of coMra therapy. The first course consisted of eight treatments, administered once daily. Following this initial intervention, the patient reported significant improvement: the abdominal pain largely subsided, except during instances of prolonged stress or dietary indiscretion. Furthermore, her stool frequency normalized, and the feelings of weakness and malaise resolved.

Long-Term Maintenance and Follow-Up

The second course of coMra therapy was completed one year later. During the interval between the two courses, the patient experienced only minor fluctuations in her well-being, typically occurring three to four months after her initial treatment. These brief periods of discomfort resolved spontaneously within a few days. The patient noted that any temporary deterioration in her condition was directly linked to prolonged non-compliance with her dietary requirements, which had necessitated the use of painkillers.

Prior to beginning the second course of treatment, the patient reported renewed pain in the abdominal and liver regions. The response to the second course was highly positive; abdominal pain dissipated after only two or three sessions, her stool returned to a normal consistency, and she reported a marked improvement in the quality of her sleep.

Given the success of these interventions, it was recommended that the patient repeat the coMra therapy protocol every three to four months, depending on her overall state of health, to maintain these gains and support ongoing digestive balance.